Epilepsy Article

Article Summary:
In 2018, CBD (cannabidiol) was approved for treating severe early-onset epilepsy forms like Dravet syndrome and Lennox-Gastaut syndrome, following successful clinical trials demonstrating its efficacy in reducing seizure frequency. Recently, researchers from Northwestern University Feinberg School of Medicine conducted the BECOME study to explore CBD’s impact on non-seizure symptoms in epilepsy patients. Their findings, published in Epilepsy Research, revealed significant improvements reported by 85% of caregivers surveyed. These improvements encompassed areas such as alertness, cognition, emotional functioning, sleep, and physical activities. The study involved 498 participants using Epidiolex®, an oral CBD solution, alongside existing anti-seizure medications, highlighting CBD’s potential beyond seizure management in epilepsy treatment.